Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

ABSTRACT

Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims the benefit under 35 U.S.C. § 119(e) ofPCT Application No. US2011/026594, filed Mar. 1, 2011, and U.S.Provisional Patent Application No. 61/438,890 filed on Feb. 2, 2011.

BACKGROUND Technical Field

The present invention generally relates to bakuchiol compositions andtheir use for treatment of post inflammatory hyperpigmentation.

Description of the Related Art

Post inflammatory hyperpigmentation (PIH) is a unique skin pigmentationcondition that involves increased melanin synthesis and deposition. PIHis also characterized by apoptosis of melanocyte cells due to oxidativestress and assaults from mediators and cytokines of inflammatory andimmune responses. The melanin deposition (i.e., hyperpigmentation)occurs beyond the epidermal level, with significant melanin beingreleased into the papillary dermis and trapped by large immune cells.These unique histological characteristics of PIH present a number ofdifficulties for treatment of PIH with traditional agents.

Common treatments for PIH are focused on prevention of further pigmentdevelopment by controlling inflammation with corticosteroids and usingphotoprotection agents. Chemical peeling compounds, such as salicylicacid and glycolic acid, are also used to facilitate the skin renewalfunction and to remove or diminish the pigmentation. Topical retinoidshave also been used to treat PIH, but such methods require up to 40weeks before significant benefits are seen.

Tyrosinase inhibitors, or skin whiteners, such as hydroquinone, azelaicacid, kojic acid and licorice extract, have also been employed fortreatment of PIH. One significant disadvantage of using traditional skinwhitening agents or tyrosinase inhibitors is the non-specificdiscolorization of the regular skin near the PIH site. This effectreduces the color of the background skin and makes the PIH sites moreprominent. Thus, these agents must be applied very carefully over thesite of the PIH. In addition, tyrosinase inhibitors are only effectivefor epidermal hyperpigmentation since this is the location of melaninsynthesis by tyrosinase. Because post inflammatory pigmentation is in adeep layer of the skin (e.g., papillary dermis), it takes more than 6months of continued application of hydroquinone medication before visualchanges of the dark marks are seen. Finally, hydroquinone type skinwhiteners or tyrosinase inhibitors are associated with side effectsincluding skin irritation, dryness, teratogenicity and induction ofvitilago and skin cancers.

Post inflammatory hyperpigmentation can be derived from endogenousinflammatory skin disorders such as acne, atopic dermatitis, allergiccontact dermatitis, incontinent pigmenti, lichen planus, lupuserythematosus, morphea. Other causes of PIH include exogenousinflammatory stimuli such as mechanical trauma, ionizing and nonionizingradiation, burns, laser therapies and skin infections. Currenttherapeutic agents for the above skin disorders are ineffective forpreventing, alleviating, reducing or treating PIH. For example, theabove skin disorders are often treated with anti-inflammatory agents,such as retinoids, COX inhibitors (e.g., salicylic acid), nonsteroidalanti-inflammatory drugs (NSAIDs), antimicrobial agents or hormonaldrugs, but these treatments have been shown to be ineffective againstPIH.

While significant advances have been made in the field, there continuesto be a need in the art for methods for preventing, alleviating,reducing or treating excess pigmentation. For example, methods fortreatment of post inflammatory hyperpigmentation are needed. The presentinvention fulfills these needs and provides further related advantages.

BRIEF SUMMARY

In general terms, the current invention is directed to methods forpreventing, alleviating, reducing or treating excess pigmentation. Theexcess pigmentation may be a result of a condition derived from aninflammatory skin condition. For example, one embodiment of the presentinvention is a method for preventing, alleviating, reducing or treatingpost inflammatory hyperpigmentation (PIH). Such PIH may be derived fromany number of skin disorders, including acne. The method comprisesadministering an effective amount of a composition comprising bakuchioland less than 500 ppm total furanocoumarin impurities to a mammal.

In contrast to other skin lightening agents, the presently disclosedbakuchiol compositions are not tyrosinase inhibitors. Thus, thedisclosed compositions specifically decolorize at the PIH site and areuseful for treating hyperpigmentation in the deep layers of skin (e.g.,papillary dermis). Accordingly, the presently disclosed methods comprisecertain advantages over previous methods for treatment ofhyperpigmentation and/or PIH.

Accordingly, one embodiment of the present disclosure is directed to amethod for preventing, alleviating, reducing or treating excesspigmentation resulting from a condition derived from an inflammatoryskin disorder, the method comprising administering to a mammal aneffective amount of a composition comprising bakuchiol, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier and less than 500 ppm total furanocoumarinimpurities.

In some embodiments, the condition is post inflammatoryhyperpigmentation. In other embodiments, the composition comprises lessthan 100 ppm total furanocoumarin impurities. In other embodiments, thefuranocoumarin impurities comprise psoralen, isopsoralen or combinationsthereof. In certain embodiments, the composition shows no tyrosinaseinhibition activity relative to a kojic acid control.

In yet other embodiments, the bakuchiol is chemically synthesized orisolated from a plant. For example, in some embodiments the bakuchiol isisolated from a plant. In some further embodiments, the plant is fromthe Psoralea genus of plants, for example, Psoralea corylifolia L.(Luguminosae) or Psoralea glandulosa L. (Papilionaceae).

In other embodiments, the bakuchiol is isolated from seeds, stems, bark,twigs, tubers, roots, root bark, young shoots, rhixomes, flowers orother reproductive organs, leaves or other aerial parts, or combinationsthereof.

In some other embodiments, the post inflammatory hyperpigmentation (PIH)is derived from acne, atopic dermatitis, allergic contact dermatitisincontinent pigmenti, lichen planus, lupus erythematosus, morphea,mechanical trauma, ionizing or nonionizing radiation, burns, laser ordrug therapies, skin infection or combinations thereof. For examples, incertain aspects the post inflammatory hyperpigmentation (PIH) is derivedfrom acne.

In other embodiments, the composition comprises 0.001% to 99.9% by totalweight of bakuchiol and a pharmaceutically, dermatologically orcosmetically acceptable carrier. For example, in some aspects thecomposition comprises from 0.1% to 2.0% by total weight of bakuchiol,1.0% by total weight of bakuchiol or 0.5% by total weight of bakuchiol.

In other embodiments, the dermatologically acceptable carrier comprisesa nonsticking gauze, a bandage, a swab, a cloth wipe, a patch, a mask ora protectant. In some other embodiments, the cosmetically acceptablecarrier comprises a cleanser or an antiseptic.

In some aspects, the composition is formulated for topicaladministration. For example, in some aspects the composition furthercomprises a cream, a lotion, an ointment, a gel, an emulsion, a liquid,a paste, a soap, a powder or combinations thereof.

In other embodiments the composition further comprises an adjuvant, skinpenetration enhancer or liposomes. In yet other embodiments, theadjuvant comprises α-hydroxyacids, salicylic acid, linoleic acid,retinoids, benzoyl peroxide, sodium sulfacetamide, clindamycin,erythromycin, dapsone, tetracycline, doxycyclin, minocyclin, zinc,estrogen or derivatives thereof, anti-androgens, sulfur,corticosteroids, cortisone, tazarotene, curcumin extract, acaciaextract, scutellaria extract, green tea extract, grape seed extract orcombinations thereof.

In certain embodiments, the composition is formulated in a capsule, forexample, controlled release capsule. In other embodiments, thecomposition is administered topically, by aerosol, by suppository,intradermically, intramuscularly or intravenously.

In some aspects, the method prevents excess pigmentation. In otheraspects, the method alleviates excess pigmentation. In yet otheraspects, the method reduces excess pigmentation. In still other aspects,the method treats excess pigmentation.

In other embodiments, the excess pigmentation occurs in a deep layer ofskin, for example, in a papillary dermis layer of skin. In otherembodiments, the method further comprises reducing super oxide anion. Insome other embodiments, the method further comprises reducingmelanogenesis. In yet other embodiments, the method further comprisesreducing melanocyte proliferation. In still other embodiments, themethod further comprises preventing melanocyte apotosis.

In certain other embodiments, the mammal is a human. In some otherembodiments, the mammal is in need of preventing, alleviating, reducingor treating excess pigmentation resulting from a condition derived froman inflammatory skin disorder. For example, the mammal may be in need oftreatment for PIH.

In another embodiment, the present disclosure is directed to a methodfor reducing melanogenesis, reducing melanocyte proliferation orpreventing melanocyte apotosis, the method comprising administering to amammal an effective amount of a composition comprising bakuchiol, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier and less than 500 ppm total furanocoumarinimpurities. In some further embodiments, the method further comprisesreducing super oxide anion.

In other embodiments, the composition comprises less than 100 ppm totalfuranocoumarin impurities. In other embodiments, the furanocoumarinimpurities comprise psoralen, isopsoralen or combinations thereof. Incertain embodiments, the composition shows no tyrosinase inhibitionactivity relative to a kojic acid control.

In yet other embodiments, the bakuchiol is chemically synthesized orisolated from a plant. For example, in some embodiments the bakuchiol isisolated from a plant. In some further embodiments, the plant is fromthe Psoralea genus of plants, for example, Psoralea corylifolia L.(Luguminosae) or Psoralea glandulosa L. (Papilionaceae).

In other embodiments, the bakuchiol is isolated from seeds, stems, bark,twigs, tubers, roots, root bark, young shoots, rhixomes, flowers orother reproductive organs, leaves or other aerial parts, or combinationsthereof.

In some embodiments, the melanogenesis, the melanocyte proliferation orthe melanocyte apotosis is a result of post inflammatoryhyperpigmentation (PIH). In some other embodiments, the postinflammatory hyperpigmentation (PIH) is derived from acne, atopicdermatitis, allergic contact dermatitis, incontinent pigmenti, lichenplanus, lupus erythematosus, morphea, mechanical trauma, ionizing ornonionizing radiation, burns, laser or drug therapies, skin infection orcombinations thereof. For examples, in certain aspects the postinflammatory hyperpigmentation (PIH) is derived from acne.

In other embodiments, the composition comprises 0.001% to 99.9% by totalweight of bakuchiol and a pharmaceutically, dermatologically orcosmetically acceptable carrier. For example, in some aspects thecomposition comprises from 0.1% to 2.0% by total weight of bakuchiol,1.0% by total weight of bakuchiol or 0.5% by total weight of bakuchiol.

In other embodiments, the dermatologically acceptable carrier comprisesa nonsticking gauze, a bandage, a swab, a cloth wipe, a patch, a mask ora protectant. In some other embodiments, the cosmetically acceptablecarrier comprises a cleanser or an antiseptic.

In some aspects, the composition is formulated for topicaladministration. For example, in some aspects the composition furthercomprises a cream, a lotion, an ointment, a gel, an emulsion, a liquid,a paste, a soap, a powder or combinations thereof.

In other embodiments the composition further comprises an adjuvant, skinpenetration enhancer or liposomes. In yet other embodiments, theadjuvant comprises α-hydroxyacids, salicylic acid, linoleic acid,retinoids, benzoyl peroxide, sodium sulfacetamide, clindamycin,erythromycin, dapsone, tetracycline, doxycyclin, minocyclin, zinc,estrogen or derivatives thereof, anti-androgens, sulfur,corticosteroids, cortisone, tazarotene, curcumin extract, acaciaextract, scutellaria extract, green tea extract, grape seed extract orcombinations thereof.

In certain embodiments, the composition is formulated in a capsule, forexample, controlled release capsule. In other embodiments, thecomposition is administered topically, by aerosol, by suppository,intradermically, intramuscularly or intravenously.

In some aspects, the method prevents excess pigmentation. In otheraspects, the method alleviates excess pigmentation. In yet otheraspects, the method reduces excess pigmentation. In still other aspects,the method treats excess pigmentation. In some embodiments, the excesspigmentation occurs in a deep layer of skin, for example, in a papillarydermis layer of skin.

In some other embodiments, the method reduces melanogenesis. In yetother embodiments, the method reduces melanocyte proliferation. In stillother embodiments, the method prevents melanocyte apotosis.

In certain other embodiments, the mammal is a human. In some otherembodiments, the mammal is in need of treatment to reduce melanogenesis,reduce melanocyte proliferation or prevent melanocyte apotosis.

In still other embodiments, the composition further comprises salicylicacid or a pharmaceutically acceptable salt thereof.

Other embodiments of the present disclosure are directed to a method oftreating inflammatory or non-inflammatory lesions, the method comprisingadministering an effective amount of a composition comprising bakuchiolor pharmaceutically acceptable salt thereof and salicylic acid or apharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable carrier to a mammal. For example, in some embodiments thelesions comprise inflammatory acne lesions. In other embodiments, themethod treats inflammatory and non-inflammatory lesions.

In certain other embodiments of the foregoing, the mammal is a human. Insome other embodiments, the mammal is in need of treatment ofinflammatory or non-inflammatory lesions.

In other embodiments, the present invention includes a compositioncomprising bakuchiol or pharmaceutically acceptable salt thereof andsalicylic acid or a pharmaceutically acceptable salt and apharmaceutically acceptable carrier. In certain embodiments, thecomposition is formulated for topical administration.

These and other aspects of the invention will be apparent upon referenceto the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

In the figures, identical reference numbers identify similar elements.The sizes and relative positions of elements in the figures are notnecessarily drawn to scale and some of these elements are arbitrarilyenlarged and positioned to improve figure legibility. Further, theparticular shapes of the elements as drawn are not intended to conveyany information regarding the actual shape of the particular elements,and have been solely selected for ease of recognition in the figures.

FIG. 1 depicts a chromatogram of bakuchiol, psoralen and isopsoralenstandards.

FIG. 2 shows chromatograms of bakuchiol compositions before and afterhydrolysis.

FIG. 3 presents data showing the strong antioxidant properties ofbakuchiol compositions.

FIG. 4 is a graph of tyrosinase inhibition activity of bakuchiolcompositions and kojic acid.

FIG. 5 shows changes in PIH severity of individual test subjects.

FIG. 6 presents a graph of the percent change of PIH affected facialarea of individual test subjects.

FIG. 7 demonstrates mean percentage change in PIH and PIH severity offive test subjects.

FIG. 8 depicts the mean grade level reduction of PIH and PIH severity ateach visit compared to baseline.

FIG. 9 shows photos of two study participants at various time intervals.

DETAILED DESCRIPTION

In the following description, certain specific details are set forth inorder to provide a thorough understanding of various embodiments.However, one skilled in the art will understand that the invention maybe practiced without these details. In other instances, well-knownstructures have not been shown or described in detail to avoidunnecessarily obscuring descriptions of the embodiments. Unless thecontext requires otherwise, throughout the specification and claimswhich follow, the word “comprise” and variations thereof, such as,“comprises” and “comprising” are to be construed in an open, inclusivesense, that is, as “including, but not limited to.” Further, headingsprovided herein are for convenience only and do not interpret the scopeor meaning of the claimed invention.

Reference throughout this specification to “one embodiment” or “anembodiment” means that a particular feature, structure or characteristicdescribed in connection with the embodiment is included in at least oneembodiment. Thus, the appearances of the phrases “in one embodiment” or“in an embodiment” in various places throughout this specification arenot necessarily all referring to the same embodiment. Furthermore, theparticular features, structures, or characteristics may be combined inany suitable manner in one or more embodiments. Also, as used in thisspecification and the appended claims, the singular forms “a,” “an,” and“the” include plural referents unless the content clearly dictatesotherwise. It should also be noted that the term “or” is generallyemployed in its sense including “and/or” unless the content clearlydictates otherwise.

Definitions

As used herein, and unless the context dictates otherwise, the followingterms have the meanings as specified below.

“Bakuchiol” as used herein refers to the compound having the followingformula:

wherein the benzylic double-bond may be either cis or trans. As usedherein, bakuchiol includes pharmaceutically acceptable salts andtautomers of bakuchiol. Phenolic compounds structurally related tobakuchiol are also included within this definition.

“Bakutrol™” is a composition comprising bakuchiol and may also furthercomprise fatty acids extracted from Psoralea plants.

“UP256” refers to a 0.5% (wt/wt) formulation of bakuchiol.

“Preventing”, “prevention” and “prevent” in the context of the disclosedmethods all refer to prophylactic methods which hinder or stop theoccurrence of a particular condition, for example PIH.

“Alleviating”, “alleviation” and “alleviate” in the context of thedisclosed methods all refer to lessening or mitigating the effects orsymptoms of a particular condition, for example PIH.

“Reducing”, “reduction” and “reduce” in the context of the disclosedmethods all refer to decreasing the effects or symptoms of a particularcondition, for example PIH.

“Treating”, “treatment” and “treat” in the context of the disclosedmethods all refer to techniques or methods intended to improve thesymptoms of or decrease or stop the occurrence of a particularcondition, for example PIH.

“Impurity” includes any substance that is not wanted in the bakuchiolcomposition, typically resulting from the isolation of bakuchiol fromnatural sources. The term impurity includes, but is not limited tofuranocoumarin compounds including, but not limited to, psoralen,isopsoralen and other coumarin type impurities. Impurities also refer toimpurities resulting from synthetic processes to obtain thesecompositions.

“Therapeutic” includes treatment and/or prophylaxis. When used,therapeutic refers to humans as well as other animals.

“Pharmaceutically, cosmetically or therapeutically effective dose oramount” refers to a dosage level sufficient to induce a desiredbiological or functional result. That result may be the alleviation ofthe signs, symptoms or causes of a disease, a skin condition or anyother alteration of a biological system that is desired.

“Placebo” refers to the substitution of the pharmaceutically ortherapeutically effective dose or amount dose sufficient to induce adesired biological that may alleviate the signs, symptoms or causes of adisease with a non-active substance.

A “host” or “subject” or “patient” is a living subject, human or animal,into which the compositions described herein are administered. Thus, thecompositions described herein may be used for veterinary as well ashuman applications and the terms “patient” or “subject” or “host” shouldnot be construed in a limiting manner. In the case of veterinaryapplications, the dosage ranges can be determined as described below,taking into account the body weight of the animal.

As noted above, one embodiment of the present disclosure relates to useof a composition comprising bakuchiol essentially free of furanocoumarinimpurities for prevention, alleviation, reduction or treatment of excesspigmentation resulting from a condition derived from an inflammatoryskin disorder. For example, the disclosed methods are useful fortreatment of post inflammatory hyperpigmentation (PIH). In certainembodiments, the PIH may be derived from acne. The disclosed method hasdemonstrated human clinical efficacy in prevention, alleviation,reduction, and treatment of post inflammatory hyperpigmentation derivedfrom skin disorders such as acne, atopic dermatitis, allergic contactdermatitis, incontinent pigmenti, lichen planus, lupus erythematosus,morphea; and post inflammatory hyperpigmentation caused by mechanicaltrauma, ionizing and nonionizing radiation, burns, laser and drugtherapies, and skin infections by using a synthetic bakuchiol orfuranocoumarin free Psoralea extract bakuchiol composition. These andother aspects and various embodiments of the present disclosure willbecome evident upon reference to the description which follows.

A. Bakuchiol Compositions

In one embodiment, the present disclosure provides a compositioncomprising bakuchiol, which is substantially free of impurities,particularly furanocoumarin impurities. This composition is alsoreferred to herein as Bakutrol™. In some embodiments, the composition isobtained by organic synthesis from simple compounds as demonstrated inthe literature (Hongli Chen and Yuanchao Li, Letters in OrganicChemistry, 2008, 5, 467-469) or from a plant. In certain embodiments,the bakuchiol composition is isolated from a plant. Plant sources ofbakuchiol include the family of plants including, but not limited toLuguminosae, Papilionaceae, Lauraceae and Magnoliaceae and the genus ofplants including, but not limited to Psorlea, Sassafras, Magnolia andAstractylodes. For example, the bakuchiol compositions may be isolatedfrom Psoralea corylifolia L. (Luguminosae) or Psoralea glandulosa L.(Papilionaceae). The compositions may be obtained from the whole plantor from one or more individual parts of the plant including, but notlimited to the seeds, stems, bark, twigs, tubers, roots, root bark,young shoots, rhixomes, flowers and other reproductive organs, leavesand other aerial parts or combinations thereof. Methods for isolation ofbakuchiol from plants may include solvent extraction, supercriticalfluid extraction, distillation, physical compressing or combinationsthereof.

Bakuchiol, the structure of which is illustrated below, is a phenoliccompound having a single hydroxyl group on the aromatic ring and anunsaturated hydrocarbon chain. Although represented as trans in thestructure below, the benzylic double bond of bakuchiol may also be cis.

The amount of Bakuchiol (i.e., weight percent (w/w %)) in the purifiedplant extract depends on the method of extraction and the extent ofpurification of the crude extract. In one embodiment the amount ofbakuchiol in the extract is in the range from 13.7% to 29.1% as shown inthe Table 2. In other embodiments the amount of bakuchiol in the extractis at least 30%, at least 35%, at least 40%, at least 45%, at least 50%,at least 60%, at least 70%, at least 80% or at least 90%. In certainembodiments, the amount of Bakuchiol in the extract is 100%. In othercertain embodiments, the amount of bakuchiol in the composition is notless than 60%. Examples 6-8 provide examples of extracts comprisingvarious amounts of bakuchiol.

Although bakuchiol is a biologically active natural product having agreat deal of potential for use in the prevention and treatment ofvarious diseases and conditions, there are a number of limitationsassociated with the use of this compound. Some limitations include itslow concentration in natural sources and the presence of co-existingtoxic components in the bakuchiol source. The impurities present in thebakuchiol compositions will vary with the source of the bakuchiol. Forexample, psoralens, also known as furanocoumarins, are naturallyoccurring secondary metabolites in Psoralea genus plants (a source ofbakuchiol) and also exist in many fruits and vegetables. Examples offuranocoumarins often found co-existing with bakuchiol include psoralenand isopsoralen.

A number of health risks have been associated with the handling, topicalapplication and ingestion of psoralen-containing plants and syntheticpsoralens. Psoralens are well known to be phototoxic agents, whichincrease the sensitivity of skin to ultra violet radiation and promotesskin cancer (Epstein (1999) Med. Surg. 18(4):274-284). Psoralen has beenshown to induce growth inhibition in rats (Diawara et al. (1997) CancerLett. 114(1-2):159-160). Gonadal toxicity from crude extracts ofPsoralea plants has been linked directly with the disruption of thehypothalamus-pituitary-gonadal axis (Takizawa et al. (2002) J.Toxicological Sciences 27(2):97-105). Oral administration of thepsoralens, bergapten (5-methoxypsoralen) and xanthotoxin(8-methoxypsoralen), in the diet of female rats reduced birthrates, thenumber of implantation sites, pups, corpora lutea, full and emptyuterine weight and circulating estrogen levels in a dose-dependentmanner (Diawara et al. (1999) J. Biochem. Molecular Toxicology13(3/4):195-203). Psoralens have also been shown to induce the mRNAs ofthe liver enzymes CYPlAI and UGT1A6, suggesting that enhanced metabolismof estrogens by psoralens may explain the reproductive toxicity and theobserved reduction of ovarian follicular function and ovulation (Diawaraet al. (May-June 2003) Pediatr Pathol Mol Med. 22(3):247-58.) Because ofthe toxicity of furanocoumarins, it is important to remove psoralen andisopsoralen from bakuchiol compositions intended for treating postinflammatory hyperpigmentation or other conditions.

Psoralen and isopsoralen account for about 0.1-2% of the dry weight ofPsoralea seeds and about 1-20% of the weight in solvent orsuper-critical fluid extracts. Crude extracts from a Psoralea genusplant can be obtained by solvent extraction, or super-critical fluidextraction, distillation, physical compressing or a combination of aboveextraction methods. An enriched Bakuchiol composition can be obtained bychromatographic separations, solvent partitions (India patentpublication #00570/KOL/2005), distillations, recrystallizations andother wet chemistry and physical processes. Published US PatentApplication No. 2006/0251749, which is hereby incorporated by referencein its entirety, discloses a solvent extraction followed byhydroxylation to break down furanocoumarin rings and obtain an enrichedbakuchiol composition essentially free of furanocoumarin impurities(e.g., less than 500 ppm, or less than 100 ppm furanocoumarinimpurities). The published method comprises the steps of extraction ofthe compound from a plant source, hydrolysis of the crude extract with abasic solution under heat, and purification by a method including butnot limited to column chromatography, extraction followed bycrystallization, solvent partition, recrystallization and combinationsthereof. The present Applicants have discovered that such a compositionof a bakuchiol enriched Psoralea extract essentially free offuranocoumarin impurities can be utilized for prevention, alleviation,reduction or treatment of excess pigmentation. For example, thedisclosed bakuchiol compositions are effective for prevention,alleviation, reduction, or treatment of post inflammatory hyperpigmentation (PIH).

The present disclosure is also directed to methods for isolating andpurifying crude compositions of bakuchiol and related compounds obtainedfrom natural sources. The method for isolating and purifying thesecompositions comprises the steps of extraction of the compounds from aplant source, hydrolysis of the crude extract with a basic solution, andpurification by a method including but not limited to columnchromatography, extraction followed by crystallization, solventpartition, recrystallization and combinations thereof. Crude extractspurified in this manner are essentially free of furanocoumarinimpurities such as psoralen and isopsoralen. Thus, the potentialphototoxicity, topical irritation, carcenogenecity, and reproductivetoxicity associated with these compounds are essentially eliminated.

In certain embodiments, the disclosed compositions comprise less than500 ppm, less than 250 ppm, less than 100 ppm, or less than 50 ppm totalfuranocoumarin impurities. The concentration of furanocoumarinimpurities may be determined by any means known to one skilled in theart. For example, in one embodiment the furanocoumarin content may bedetermined by HPLC.

The efficiency of bakuchiol extraction from plant sources was evaluatedusing six different organic solvent systems under two sets of extractionconditions as described in Example 2. The results are set forth in Table2. With reference to Table 2, it can be seen that bakuchiol can beextracted from Psoralea plants with any number of organic solventsand/or combinations thereof. The amount of bakuchiol in the variousextracts ranged from 13.7% to 29.1% by weight. Other extraction methodsinclude, but are not limited to, CO₂ super-critical fluid extraction andwater distillation. Squeeze exudates from fresh plant parts such asseeds, can also be utilized to obtain Bakuchiol compositions fromnatural sources.

The efficacy of purification of crude bakuchiol extracts by columnchromatography is demonstrated in Example 3 and Table 3. Eight differenttypes of resins were evaluated specifically for their ability toseparate bakuchiol from furanocoumarin impurities. Both silica gel andCG-161 resins demonstrated satisfactory separation. Columnchromatographic separation of crude plant extracts on an industrialscale, however, is typically not economically feasible because itrequires expensive equipment and reagents and experienced personnel. Theextremely low loading capacity of these samples due to the complexity ofcrude plant extracts also makes industrial scale column chromatographydifficult.

Example 4 describes an economical method for separating bakuchiol fromfuranocoumarin impurities. The method comprises treatment ofcompositions containing furanocoumarin impurities with a base. Asillustrated by the following Scheme 1, using NaOH for purposes ofillustration, heating with a base opens up the lactone ring of thefuranocoumarins, thereby converting them into the corresponding salts ofcarboxylic acids. These salts can then be easily separated from theremainder of the mixture by a variety of methods. The disclosed methodallows preparation of bakuchiol compositions essentially free offuranocoumarin impurities (e.g., less than 500 ppm). Such highly purebakuchiol compositions are not attainable using standard chromatographictechniques without the disclosed hydrolysis.

The basic solution may comprise any base capable of opening lactonerings, including, but not limited to sodium hydroxide, potassiumhydroxide, calcium hydroxide, lithium hydroxide or combinations thereof.The solution can have different concentration and pH values to maximizethe conversion to the acid salt. The reaction mixture can also be heatedunder different temperature and pressures to maximize the reaction rate,efficiency and yield.

The course of the reaction can be followed by HPLC to ensure completeconversion of the furanocoumarins into their respective carboxylic acidsalts. HPLC chromatograms of the crude composition before and afterhydrolysis are illustrated in FIG. 2. Upon completion of the reaction(as determined by HPLC), the reaction solution can be processed usingvarious methods, including but are not limited to column chromatography,crystallization, solvent partition, precipitation, solvent wash orcombinations thereof. Organic solvents that can be used for solventpartitioning include, but are not limited to petroleum ether, ethylacetate, ethyl ether, hexane, chloroform, propanol, butanol, andmethylene chloride, as well as other water immiscible organic solvents.

Crude extracts purified in this manner are essentially free offuranocoumarin impurities such as psoralen and isopsoralen. For example,the purified extract may comprise less than 500 ppm, less than 250 ppm,less than 100 ppm or even less than 50 ppm furanocoumarin impurities.Additionally, the color of these highly pure furanocoumarin free,bakuchiol compositions is light brown or red and they are very stablewith respect to both color and composition of the active agent, makingthem particularly suitable for formulation, storage and cosmeticapplications.

Also included in the present disclosure is a method for analyzingcompositions of bakuchiol, which enables detection and quantification ofimpurities. In this embodiment, the method for analyzing compositions ofbakuchiol is comprised of the step of analyzing the compositions byhigh-pressure liquid chromatography (HPLC). Analysis by HPLC enablesquantification of the various components in the mixture and alsoprovides a means to track bakuchiol, psoralen, isopsoralen and othernatural components in Psoralea plants to guide the extraction,hydrolysis and purification processes. A method for analyzingcompositions of bakuchiol using high pressure liquid chromatography(HPLC) is described in Example 1 (Table 1).

B. Treatment of Excess Pigmentation with Bakuchiol Compositions

One embodiment of the present disclosure relates to use of a compositioncomprising bakuchiol essentially free of furanocoumarin impurities forprevention, alleviation, reduction or treatment of excess pigmentationresulting from a condition derived from an inflammatory skin disorder.For example, the disclosed methods include prevention, alleviation,reduction or treatment of post inflammatory hyperpigmentation (PIH). Incertain embodiments, the PIH may be derived from acne. The disclosureincludes the formulation of a bakuchiol composition in a typicalcosmetic vehicle and also in skin care cream, gel lotion and otherformulations as discussed in more detail below. As shown in theExamples, the present Applicants have demonstrated the un-expected humanclinical efficacy of bakuchiol compositions in prevention, alleviation,reduction or treatment of post inflammatory hyperpigmentation (PIH)derived from skin disorders such as acne, atopic dermatitis, allergiccontact dermatitis, incontinent pigmenti, lichen planus, lupuserythematosus, morphea; and post inflammatory hyperpigmentation causedby mechanical trauma, ionizing and nonionizing radiation, burns, laserand drug therapies, and skin infections.

The disclosed methods comprise administering to a mammal (e.g., a humanpatient) an effective amount of a composition comprising bakuchiol,which is substantially free of furanocoumarin impurities. For example,the compositions may comprise less than 500 ppm furanocoumarinimpurities. The composition may comprise from about 0.0001% to about100% bakuchiol. For example, in certain embodiments the compositioncomprises from about 0.1% to about 2% bakuchiol or from about 0.5% toabout 1% bakuchiol. In other examples the composition comprises about0.5% or about 1.0% bakuchiol. In certain embodiments, the mammal is ahuman, and in other embodiments the mammal is in need of prevention,alleviation, reduction or treatment of excess pigmentation resultingfrom a condition derived from an inflammatory skin disorder, for examplethe mammal may be in need of treatment for PIH.

The present disclosure demonstrates unexpectedly unique biologicalproperties of synthetic or natural bakuchiol compositions. As shown inExample 5 and Table 4, a Bakutrol composition comprising about 57.35%bakuchiol has unexpectedly high anti-oxidation capacity, especiallyagainst super oxide anion (>69,000 μmole TE/g) with a total ORAC valueagainst five predominant reactive species at >92,000 μmole TE/g.

Superoxide is an anion with the chemical formula O₂ ⁻. A chronicinflammatory condition, such as acne vulgaris, can have dramaticallyincreased superoxide anion production from keratinocytes, which arestimulated by a gram-positive anaerobic bacterium such as P. acnes(Grange P A., et al. Plos Pathogens 2009, 5(7) 1-14.). Superoxide isbiologically quite toxic and is deployed by the immune system to killinvading microorganisms. In phagocytes, superoxide is produced in largequantities by the enzyme NADPH oxidase for use in oxygen-dependentkilling mechanisms of invading pathogens. Superoxide anion and otherreactive oxygen species in the inflamed skin can also inducemelanogenesis, melanocyte proliferation and melanocyte apotosis, whichis a major causative factor of post inflammatory hyperpigmentation.Accordingly, one embodiment of the present disclosure is a method foralleviating, reducing or treating excess pigmentation resulting from acondition derived from an inflammatory skin disorder by reducingsuperoxide with a composition comprising bakuchiol essentially free offuranocoumarin impurities. In one embodiment, the condition is PIH. Inanother embodiment, the present disclosure provides a method of reducingmelanogenesis or melanocyte proliferation or inhibiting melanocyteapotosis, for example, by reducing superoxide anion. The methodcomprises administering an effective amount of a composition comprisingbakuchiol essentially free of furanocoumarin impurities to a mammal. Incertain embodiments, the mammal is a human, and in other embodiments themammal is in need of reducing melanogenesis or melanocyte proliferationor inhibiting melanocyte apotosis.

As demonstrated in Example 6 and FIG. 3, a composition comprising 77.02%bakuchiol, which is substantially free of impurities, particularlyfuranocoumarin impurities showed protective effect on oxidative stressinduced by 4-teriaybutylphenol (4-TBP). The cytotoxicity to melanocytesfrom the reactive oxygen species generated by 4-TBP was protected by thebakuchiol compositions at the two concentrations tested. While notwishing to be bound by the theory, the present Applicants believe theunexpected clinical benefits from a synthetic or natural bakuchiolcomposition of reducing, alleviating, preventing or treating postinflammatory hyperpigmentation (PIH) is derived from its unique andunexpected capacity to neutralize reactive oxygen species, especiallysuperoxide anion, and protect melanocytes from oxidative stress underinflammation conditions that lead to reduced epidermal melanosis and/ordermal melanosis.

In addition to its unexpectedly high anti-oxidation capacity, thepresent Applicants have discovered that the disclosed bakuchiolcompositions are not tyrosinase inhibitors. This is in contrast to otherreports which disclose bakuchiol as a skin whitening agent viatyrosinase inhibition (Japanese Patent No. P1107123). This unexpecteddiscovery led the present Applicants to the currently disclosed methodsfor treating PIH where the pigmentation occurs in a deep skin layer andtyrosinase inhibitors are ineffective. The lack of tyrosinase inhibitionof the disclosed bakuchiol compositions is shown in Example 7 and FIG.4. Both pure Bakuchiol (100%) and enriched Bakuchiol (77.02%) with notmore than 100 ppm furanocoumarins from natural sources have notyrosinase inhibition function at eight different dosages.

Compositions comprising bakuchiol at concentrations of 86.54% and 77.02%bakuchiol, were evaluated for their safety profiles. As shown in Example9 and Table 6, based on in vitro and human clinical tests, the Bakutrol(UP256) compositions showed no eye irritation, no skin irritation on thenormal or scarified skin, no skin contact sensitization, nophototoxicity and no mutagenic toxicity. The topical creams of theBakuchiol composition were well tolerated in all human and in vitrotests.

As demonstrated in Example 10, a natural bakuchiol composition(Bakutrol™) comprising 77.02% bakuchiol and less than 100 ppmfuranocoumarin extracted and enriched from the seeds of Psoraleacorylifolia was tested in a human clinical trial on subjects with postinflammatory hyperpigmentation (PIH) derived from mild or moderate acnevulgaris. The bakuchiol composition was formulated at 0.5% bakuchiol fortopical application. After daily topical application of the 0.5%Bakutrol cream, a dramatic reduction of post inflammatoryhyperpigmentation (PIH) was observed in all five subjects. As shown inFIG. 5, all five subjects had at least one grade level reduction of PIHseverity. More than 50% improvement of PIH affected facial area wasachieved after 8 weeks of continued topical application of the 0.5%Bakutrol cream (FIG. 6). The mean percentage and absolute grade levelimprovements of both PIH and its severity are summarized in FIGS. 7 & 8.Improvements of more than 40%, or more than one grade level reduction ofboth PIH and severity, were achieved as early as 4 weeks after using thebakuchiol composition. Substantial reduction of PIH on the affectedfacial skin sites is clearly evident in the photos of two subjects asshown in FIG. 9. Both subjects showed progressive improvement of skinPost-Inflammatory Hyperpigmentation (PIH) associated with mild andmoderate acnes after topical application of a Bakutrol cream.

Table 7 (Example 10) summarizes the clinical out puts for using afuranocoumarin free Bakuchiol composition (i.e., Bakutrol) in comparisonto popular acne treatment products which contain either ananti-microbial or an anti-inflammatory or combinations thereof. The datain Table 7 clearly demonstrates that the furanocoumarin free Bakuchiolcomposition not only improved inflammatory and non-inflammatory lesioncounts, but also significantly improved skin Post-InflammatoryHyperpigmentation. The P111 benefit from the Bakuchiol composition isnot expected based on its lacks of tyrosinase inhibition activity.

Table 8 (Example 11) presents data showing reduction in PIH grade (i.e.,extent of pigmentation). The data clearly shows that bakuchiol is moreeffective than both placebo and salicylic acid for treatment of PIH.Furthermore, the present applicants have also discovered that bakuchiol(or compositions comprising the same) are effective for treatment ofinflammatory lesions, such as acne lesions. Table 9 (Example 11)demonstrates the effectiveness of bakuchiol for treatment ofinflammatory lesion compared to treatment with placebo or salicylicacid.

In addition to methods comprising treatment with compositions comprisingbakuchiol, the present invention includes embodiments wherein a mammalis treated with a composition comprising bakuchiol and salicylic acid.For example, the present applicants have discovered that salicylic acidis effective for treatment of non-inflammatory lesions, while bakuchiolis effective for treatment of inflammatory lesions. Accordingly, oneembodiment of the present invention is directed to a method of treatinginflammatory lesions (e.g., acne lesions), the method comprisingadministering an effective amount of a composition comprising bakuchiolor a pharmaceutically acceptable salt thereof to a mammal. Anotherembodiment is directed to a method of treating inflammatory and/ornon-inflammatory lesions (e.g., acne lesions), the method comprisingadministering an effective amount of a composition comprising bakuchioland salicylic acid (or pharmaceutically acceptable salts thereof) to amammal. Other embodiments include treatment of non-inflammatory lesionsby administering an effective amount of a composition comprisingsalicylic acid or a pharmaceutically acceptable salt thereof to amammal. In certain embodiments of the foregoing, the mammal is a human.In other embodiments, the mammal is in need of treatment forinflammatory and/or non-inflammatory lesions, such as acne.

In addition to treatment of lesions, the combination of bakuchiol andsalicylic acid is effective for treating any of the foregoing conditions(e.g., PIH, reducing melanogenesis, reducing melanocyte proliferation orpreventing melanocyte apotosis, etc.). Accordingly, some embodiments aredirected to treatment with a composition comprising bakuchiol andsalicylic acid. Other embodiments include a composition comprisingbakuchiol or a pharmaceutically acceptable salt thereof, salicylic acidor a pharmaceutically acceptable salt thereof and a pharmaceuticallyacceptable carrier.

The foregoing methods are effective to substantially eliminateinflammatory and/or non-inflammatory lesions. For example in someembodiments the methods reduce lesions from about 1% to about 99% orfrom about 10% to about 90%. In other embodiments, the methods reducelesions by greater than 50%.

The ratio of bakuchiol to salicylic acid is not particularly limited andcan be determined by one of ordinary skill in the art based on thedesired result. For example, in some embodiments the weight ratio ofbakuchiol to salicylic acid ranges from about 1:100 to about 100:1. Inother embodiments, the weight ration ranges from about 10:90, about20:80, about 30:70, about 40:60, about 50:50, about 60:40, about 70:30,about 80:20 to about 10:90. The compositions may be formulated accordingto any of the formulations described herein.

C. Formulation of Bakuchiol Compositions

The bakuchiol compositions of the present disclosure can be formulatedby any means known to those of skill in the art. As shown in Example 8and Table 5, the compositions of the present disclosure can beformulated as pharmaceutical, cosmetic or dermatological compositions,and can include other components such as a pharmaceutically and/orcosmetically acceptable actives, excipient, adjuvant, carrier orcombinations thereof. An excipient is an inert substance used as adiluent or vehicle for dermatological and cosmetically accepted productsand drugs. Examples of such excipients include, but are not limited towater, buffers, saline, glycerin, hydrated silica, propylene glycol,aluminum oxide, carrageenan, cellulose gum, titanium dioxide, Ringer'ssolution, dextrose solution, mannitol, Hank's solution, preservativesand other aqueous physiologically balanced salt solutions. Nonaqueousvehicles, such as fixed oils, sesame oil, ethyl oleate, or triglyceridesmay also be used. Other useful formulations include suspensionscontaining viscosity enhancing agents, such as sodiumcarboxymethylcellulose, sorbitol, or dextran.

In Example 8, compositions of the present disclosure were formulated intranscutol, or caprylic triglyceride, or polysorbate-20, or purifiedwater or combinations of two or more of the above vehicle. Excipientscan also contain minor amounts of additives, such as EDTA, disodiumDDTA, BHA, BHT, diammonium citrate, nordihydroguaiaretic acid, propylgallate, sodium gluconate, sodium metabisulfite, t-butyl hydroquinone,SnCl₂, H₂O₂, and 2,4,5-trihydroxybutyrophenone, vitamin C, vitamin E,vitamin E acetate, phenonip, and other substances that enhanceisotonicity and chemical stability.

Examples of substances for adjusting the pH of the formulation includesodium hydroxide, sodium carbonate, sodium bicarbonate, pentasodiumtriphosphate, tetrasodium pyrophosphate, sodium lauryl sulfate, calciumperoxide, phosphate buffer, bicarbonate buffer, tris buffer, histidine,citrate, and glycine, or mixtures thereof. Examples of flavors include,but are not limited to thimerosal m- or o-cresol, formalin, fruitextracts and benzyl alcohol. Standard formulations can either be liquidor solids, which can be taken up in a suitable liquid as a suspension orsolution for administration. Thus, in a non-liquid formulation, theexcipient can comprise dextrose, human serum albumin, preservatives,etc., to which sterile water or saline can be added prior toadministration.

In one embodiment, the bakuchiol composition is formulated with otheractive compounds that target a different mechanism of action forreduction of skin pigmentation. Such actives include but are not limitedto, hydroquinone, monobenzylether, arbuting, deoxyarbutin, mequinol,N-acetyl-4-S-cysteaminylphenol, kojic acid, azelaic acid, glycolic acid,gentisic acid, favonoids, aloesin, stilbene and stilbene derivatives,licorice extract, bearberry extract, mulberry extract, aloe vera gel,glabridin, vitamin C derivatives, magnesium ascorbyl phosphate,tetrahexyldecyl ascorbate, vitamin e derivatives, tranexamic acid andits derivatives, biomimetric of TGF-B proteins, centaureidin,niacinamide, PAR-2 inhibitors, lectins, neoglycoproteins, resorcinol andits derivatives, and Nivitol™.

In another embodiment, the composition comprises anti-inflammatory andanti-microbial agents that can synergistically work with the bakuchiolcomposition to reduce the infection, infection related inflammation, andacceleration of epidermal turnover. Such actives include but are notlimited to α-hydroxyacids, salicylic acid, linoleic acid, retinoids,benzoyl peroxide, sodium sulfacetamide, clindamycin, erythromycin,dapsone, tetracycline, doxycyclin, minocyclin, zinc, estrogen and itsderivatives, anti-androgens, sulfur, corticosteroids, cortisone,tazarotene, curcumin extract, acacia extract, scutellaria extract, greentea extract, and grape seed extract.

In certain embodiments, the composition comprises an adjuvant or acarrier. Adjuvants are typically substances that generally enhance thebiological response of a mammal to a specific bioactive agent. Suitableadjuvants include, but are not limited to, Freund's adjuvant; otherbacterial cell wall components; aluminum, calcium, copper, iron, zinc,magnesium, stannous based salts; silica; microdermabrasion agents,polynucleotides; toxoids; serum proteins; viral coat proteins; otherbacterial-derived preparations; gamma interferon; block copolymeradjuvants, such as Hunter's Titermax adjuvant (Vaxcel™, Inc. Norcross,Ga.); Ribi adjuvants (available from Ribi ImmunoChem Research, Inc.,Hamilton, Mont.); and saponins and their derivatives such as Quil A(available from Superfos Biosector A/S, Denmark). Carriers are typicallycompounds that increase the half-life of a therapeutic composition inthe treated host. Suitable carriers include, but are not limited to,polymeric controlled release formulations, biodegradable implants,liposomes, nano-capsulation, nano-particles, bacteria, viruses, oils,esters, and glycols.

In other examples, the composition is prepared as a controlled releaseformulation, which slowly releases the composition into the host. Asused herein, a controlled release formulation comprises a composition ofbakuchiol in a controlled release vehicle. Suitable controlled releasevehicles will be known to those skilled in the art. Examples ofcontrolled release formulations are biodegradable (i.e., bioerodible)and include capsules.

In one embodiment, a suitable ointment is comprised of the desiredconcentration of UP256 (bakuchiol) that is an efficacious, nontoxicquantity generally selected from the range of 0.001% to 100% based ontotal weight of the topical formulation, from 65% to 100% (for example,75% to 96%) of white soft paraffin, from 0% to 15% of liquid paraffin,and from 0% to 7% (for example 3 to 7%) of lanolin or a derivative orsynthetic equivalent thereof. In another embodiment the ointment maycomprise a polyethylene—liquid paraffin matrix.

In one embodiment, a suitable cream is comprised of an emulsifyingsystem together with the desired concentration of UP256 (bakuchiol)synthesized and/or isolated from a single plant or multiple plants asprovided above. The emulsifying system is preferably comprised of from 2to 10% of polyoxyethylene alcohols (e.g., the mixture available underthe trademark Cetomacrogol™ 1000), from 10 to 25% of stearyl alcohol,from 20 to 60% of liquid paraffin, and from 10 to 65% of water, togetherwith one or more preservatives, for example from 0.1 to 1% ofN,N″-methylenebis[N′-[3-(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]urea](availableunder the name Imidurea USNF), from 0.1 to 1% of alkyl4-hydroxybenzoates (for example the mixture available from NipaLaboratories under the trade mark Nipastat), from 0.01 to 0.1% of sodiumbutyl 4-hydroxybenzoate (available from Nipa Laboratories under thetrade mark Nipabutyl sodium), and from 0.1 to 2% of phenoxyethanol.

In one embodiment, a suitable gel is comprised of a semi-solid system inwhich a liquid phase is constrained within a three dimensional polymericmatrix with a high degree of cross-linking. The liquid phase may becomprised of water, together with the desired amount of UP256(bakuchiol), from 0.01 to 20% of water-miscible additives, for exampleglycerol, polyethylene glycol, or propylene glycol, and from 0.01 to10%, preferably from 0.5 to 2%, of a thickening agent, which may be anatural product, for example tragacanth, pectin, carrageen, agar andalginic acid, or a synthetic or semi-synthetic compound, for examplemethylcellulose and carboxypolymethylene (carbopol); together with oneor more preservatives, for example from 0.1 to 2% of methyl4-hydroxybenzoate (methyl paraben) or phenoxyethanol-differential.Another suitable formulation, is comprised of the desired amount ofUP256 (bakuchiol), together with from 70 to 90% of polyethylene glycol(for example, polyethylene glycol ointment containing 40% ofpolyethylene glycol 3350 and 60% of polyethylene glycol 400, prepared inaccordance with the U.S. National Formulary (USNF)), from 5 to 20% ofwater, from 0.02 to 0.25% of an anti-oxidant (for example butylatedhydroxytoluene), and from 0.005 to 0.1% of a chelating agent (forexample ethylenediamine tetraacetic acid (EDTA)).

The term soft paraffin as used above encompasses the cream or ointmentbases white soft paraffin and yellow soft paraffin. The term lanolinencompasses native wool fat and purified wool fat. Derivatives oflanolin include in particular lanolins which have been chemicallymodified in order to alter their physical or chemical properties andsynthetic equivalents of lanolin include in particular synthetic orsemisynthetic compounds and mixtures which are known and used in thepharmaceutical and cosmetic arts as alternatives to lanolin and may, forexample, be referred to as lanolin substitutes.

One suitable synthetic equivalent of lanolin that may be used is thematerial available under the trademark Softisan™ known as Softisan 649.Softisan 649, available from Dynamit Nobel Aktiengesellschaft, is aglycerine ester of natural vegetable fatty acids, of isostearic acid andof adipic acid; its properties are discussed by H. Hermsdorf in Fette,Seifen, Anstrichmittel, Issue No. 84, No. 3 (1982), pp. 3-6.

The other substances mentioned hereinabove as constituents of suitableointment or cream bases and their properties are discussed in standardreference works, for example US Pharmacopoeia. Cetomacrogol 1000 has theformula CH₃(CH₂)_(m)(OCH₂CH₂)_(n)OH, wherein m may be 15 or 17 and n maybe 20 to 24. Butylated hydroxytoluene is 2,6-di-tert-butyl-p-cresol.Nipastat is a mixture of methyl, ethyl, propyl and butyl4-hydroxybenzoates.

The compositions disclosed herein may be produced by conventionalpharmaceutical techniques. Thus the aforementioned compositions, forexample, may conveniently be prepared by mixing together at an elevatedtemperature, for example 60-70° C., the soft paraffin, liquid paraffinif present, and lanolin or derivative or synthetic equivalent thereof.The mixture may then be cooled to room temperature, and, after additionof the hydrated crystalline calcium salt of mupirocin, together with thecorticosteroid and any other ingredients, stirred to ensure adequatedispersion.

Finally, bakuchiol has a partition coefficient of log P=6.13. Thepartition coefficient of a chemical compound provides a thermodynamicmeasure of its hydrophilicity/lipophilicity balance and thus itspotential bioavailability. Having a partition coefficient of 6.13 meansthis compound has high cell membrane penetration and bioavailabilitywhen formulated in a delivery system. The skin penetration of the activecompound—bakuchiol in a skin care cream was quantified in an ex-vivotest on isolated human skin. The results showed a good skin penetrationand bioavailability. In certain embodiments, the disclosed compositionscomprise a skin penetration enhancer.

D. Administration of Bakuchiol Compositions

The compositions of the present disclosure can be administered by anymethod known to one of ordinary skill in the art. For example, thedisclosed compositions can be administered internally or topically. Themodes of administration include, but are not limited to, enteral (oral)administration, parenteral (intravenous, subcutaneous, andintramuscular) administration and topical application. In certainembodiments, the compositions are administered topically.

The content of a bakuchiol composition in the finished skin careproducts for PIH can range from 0.001% to 99.9% by weight. In someembodiments, the composition comprises from 0.1% to 2% bakuchiol. Inother examples the composition comprises 0.5% or 1.0% bakuchiol. Incertain embodiments the amount of bakuchiol composition in a PIH skincare cream ranges from 0.5-1%. The methods according to this disclosurecomprise administering internally or topically to a mammal atherapeutically effective amount of a composition comprising bakuchiol,which is totally synthesized or isolated from natural sources (or acombination thereof) and is substantially free of impurities,particularly furanocoumarin impurities (e.g., less than 500 ppm).

The therapeutic agents of the instant disclosure can be administeredtopically by any suitable means known to those of skill in the art fortopically administering therapeutic compositions. Such modes ofadministration include, but are not limited to, as an ointment, gel,lotion, or cream base or as an emulsion, as a patch, dressing or mask, anonsticking gauze, a bandage, a swab or a cloth wipe. Such topicalapplication can be locally administered to any affected area, using anystandard means known for topical administration. A therapeuticcomposition can be administered in a variety of unit dosage formsdepending upon the method of administration. For particular modes ofdelivery, the therapeutic compositions can be formulated in an excipientas discussed above. A therapeutic composition of the present disclosurecan be administered to any host, preferably to mammals, and morepreferably to humans. The particular mode of administration will dependon the condition to be treated.

Regardless of the manner of administration, the specific dose iscalculated according to the approximate body weight of the host. Furtherrefinement of the calculations necessary to determine the appropriatedosage for treatment involving each of the above mentioned formulationsis routinely made by those of ordinary skill in the art and is withinthe scope of tasks routinely performed by them without undueexperimentation, especially in light of the dosage information andassays disclosed herein. These dosages may be ascertained through use ofthe established assays for determining dosages utilized in conjunctionwith appropriate dose-response data. In certain embodiments, the dose ofthe composition comprising bakuchiol ranges from 0.001 to 200 mg perkilogram of body weight.

The following examples are provided for purposes of illustration, notlimitation.

EXAMPLES Example 1 Quantification of Bakuchiol, Psoralen and Isopsoralenby HPLC

The amount of bakuchiol, psoralen and isopsoralen in the extracts,fractions, process materials, ingredients and final formulated productswere quantified by high pressure liquid chromatography (HPLC) using aPhotoDiode Array detector (HPLC/PDA). The targeted compounds were elutedfrom a Luna Phenyl-hexyl column (250 mm×4.6 mm) using an acetonitrile(ACN) or methanol & water gradient from 36% to 100% ACN over a period of12 minutes, followed by 100% ACN for three minutes. The detailed HPLCconditions used are set forth in Table 1. A chromatogram of the HPLCseparation is shown in FIG. 1. The targeted compounds were identifiedand quantified based on retention time and UV peak area usingcommercially available pure bakuchiol, psoralen and isopsoralen asquantification standards. The retention times for the bakuchiol,psoralen and isopsoralen were 18.19 minutes, 7.33 minutes and 7.95minutes, respectively.

TABLE 1 HPLC Conditions for quantification of Bakuchiol, Psoralen andIsopsoralen Column Luna Phenyl-hexyl, 150 × 4.6 mm Gradient  0-8 min 36%ACN/water  8-20 min 36% ACN/water to 100% ACN 20-23 min 100% ACN 23-28min 36% ACN/water Flow rate  1 mL/min Detection  0-11 min 246 mu (forpsoralen and angelicin, 7-8min) 11-28 min 260 nm (for bakuehiol,18-19min) Temperature 35° C. Standard 0.1 mg/mL in MeOH for bakuchiolconcentration 0.025 mg/mL for psoralen and angelicin Extract preparation0.2 mg/mL in MeOH Linear range 0.01 mg/mL to 0.15 mg/mL

Example 2 General Methods for Extraction of Bakuchiol from PsoraleaPlants

Method A—To a flask was added solvent (100 mL) and Psoralea corylifoliaseed powder (10 g), and the mixture was shaken on a wrist shaker at roomtemperature for one hour. The mixture was then passed through a filterand the filtrate collected. The extraction process was repeated one moretime with fresh solvent, the filtrates were combined, the solventremoved on a rotoevaporator and the residue dried under high vacuum.

Method B—To a flask was added solvent (50 mL) and Psoralea corylifoliaseed powder (10 g), and the mixture was refluxed for 40 min. Thesolution was then filtered and the extraction process was repeated twomore times with fresh solvent. The filtrates were combined, and thesolvent was evaporated to obtain a dried extract.

Following the above extraction methods, sample plant material wasextracted with the following solvents: dichloromethane (DCM), ethylacetate (EtOAc), acetone, methanol (MeOH), petroleum ether (BP 35-60°C.) and petroleum ether (BP 60-90° C.). The extracts and plant materialswere then analyzed by HPLC analysis as described in Example 1. Theresults are set forth in Table 2.

TABLE 2 Quantification of Various Psoralea Corylifolia ExtractsPetroleum Petroleum Petroleum Ether Ether Ether (35-60° C.) DCM EtOAeAcetone MeOH (35-60° C.) (60-90° C.) Extract wt. 0.5833 1.7535 1.67101.8932 1.8795 0.6457 0.9203 (g) % 29.1% 14.2% 13.7% 13.7% 13.9% 25.6%27.2% Baktichiol in Extract % 1.7% 2.5% 2.3% 2.6% 2.6% 2.6% 2.7%Baktichiol in Plant Method Wrist shaker Reflux (100 ml/10 g solid) (50ml/10 g solid)

Example 3 Chromatographic Methods for Purifying Bakuchiol Extracts

Various chromatographic methods were utilized for purifying bakuchiolfrom the crude solvent extract isolated from the seeds of Psoraleacorylifolia using the method described in Example 2. The efficiency of aspecific column enrichment method was demonstrated as a means ofobtaining high purity bakuchiol free of contamination byfuranocoumarins, particularly psoralen/isopsoralen contamination.Briefly, each empty column cartridge (1.3 cm internal diameter (ID) and20 mL capacity, from Bio-Rad) was packed with a different media andeluted with different solvents in an attempt to separate thefuranocoumarin impurities from bakuchiol. The fractions (10 mL perfraction) were collected in test tubes and analyzed with silica gel TLCplates developed with 20% EtOAc/petroleum ether. The targeted compounds,bakuchiol, psoralen and isopsoralen, were identified based on theirretention times, which were determined using solutions of standardcompounds. The results are set forth in Table 3. Many of the methodsdescribed in Table 3 were useful for the separation of furanocoumarinsand bakuchiol from both synthetic and natural sources, however the costof this methodology may not be economically feasible for large scaleproduction.

TABLE 3 Summary of Column Chromatographic Separation of Bakuchiol fromFuranocournarins in Crude Extracts of Psoralea Corylifolia. Column size/Elution Media Extract Loading Solvent Results A1₂O₃ (neutral) 2 mL/15mg 1. Petroleum ether Little separation (J.T. Baker) 2. EtOAc 3. MeOHXAD-4 5 mL/19 mg MeOH/water gradient in No separation (amerlite 20%increments from100% polystyrene water to 100% MeOH resin) XAD-7 8 mL/16mg Pet ether/EtOAc gradient in Some separation (amerlite 20% incrementsfrom 100% polyacrylate petroleum ether to 100% resin) MeOH MeOH/watergradient in Little separation 20% increments from 100% water to 100%MeOH Polyamide 5 mL/50 rug 1. Petroleum ether No separation 2. 5%acetone/pet. ether 3. Acetone LH-20 8 mL/50 mg Petroleum ether Noseparation Silica gel 5 mL/50 mg 1. Petroleum ether Good separation 2.15% EtOAc/pet, ether CG-71md 5 mL/50 mg 1. Petroleum ether No separation2. Acetone CG-161cd 5 mL/50 mg Petroleum ether No separation 6 mL/50 mgMeOH/water step gradient Good separation Low yield

Example 4 Hydrolysis of an Extract Isolated from the Seeds of Psoraleacorylifolia

A hexane extract or a CO₂ super-critical fluid extract of seeds ofPsoralea corylifolia, which contained about 25% bakuchiol, was mixedwith a 1M NaOH solution. The solution was heated in a reaction vessel toa temperature at or above 80° C. for at least one hour. A small portionof the solution was taken from the flask periodically and analyzed byHPLC as described in Example 1. The reaction was stopped after HPLCanalysis showed that the peaks for psoralen and isopsoralen hadcompletely disappeared. The reaction mixture was then cooled to roomtemperature and the aqueous phase was removed. After the solution waswashed multiple times with saturated a NaCl solution, the organic layerwas extracted with ethyl acetate or other organic solvents. The organicsolution was filtered, washed, dried and evaporated to yield a brownishred syrup having a bakuchiol content not less than 50% and a combinedtotal of no more than 100 ppm of psoralen and angelicin (isopsoralen).

Example 5 Anti-Oxidation Property of Furanocoumarin Free BakuchiolComposition

A natural bakuchiol composition (Lot #UP256-0906MP) comprising 57.35%bakuchiol and a combined total of less than 100 ppm psoralen andangelicin (isopsoralen) was evaluated for its antioxidant capacityagainst peroxy radicals, hydroxyl radicals, peroxynitrite, super oxideanion and singlet oxygen at Brunswick laboratories, Norton, Mass. USA.The total oxygen radical absorbance capacity of the bakuchiolcomposition was measured according to the published methodology (Ou, B.et al., J Agric and Food Chem, 2001, 49 (10): 4619-4626; Prior, R L. etal., J Agric and Food Chem, 2005, 53: 4290-4302). Results are tabulatedin Table 4.

TABLE 4 Anti-oxidation Profile of Bakutrol ™ (UP256) Test Result† UnitsAntioxidant power against perm radicals 12,845 μmole TE/gram Antioxidantpower agairist hydroxyl radicals  6,262 μmole TE/gram Antioxidant poweragainst peroxynitrite   289 μmole TE/gram Antioxidant power againstsuper oxide anion 69,929 μmole TE/gram Antioxidant power against singletoxygen  3,067 μmole TE/gram Total ORAC_(FN) (sum of above) 92,395μmoleTE/gram *The acceptable precision of the ORAC assay is <15%relative standard deviation. †Liquid samples weighed and extracted dueto viscosity. There are five predominant reactive species found in thebody; peroxyl radicals, hydroxyl rathols, peroxyilitrite, super oxideanion, and singlet oxygen. Total ORAC_(FN) provides a measure or thetotal antioxidant power of a food/nutrition product against the fivepredominant reactive species.

Example 6 Evaluation of a Bakuchiol Composition for AntioxidationProtective Effect on 4-TBP Cytotoxicity

A natural bakuchiol composition comprising 77.02% bakuchiol and acombined total of less than 100 ppm psoralen and angelicin (isopsoralen)was tested for its antioxidant property by assessing its ability toprevent 4-tertiarybutylphenol (4-TBP) induction of oxidative stressduring a 5-day treatment period using compound concentrations at the 95%viability dose. Oxidative stress was determined by assaying thegeneration of Reactive Oxygen Species (ROS) using the Image-iT LiveGreen Reactive Oxygen Species Detection Kit (InVitrogen). In this assay,carboxy-2′,7′-dichlorodihydrofluorescein diacetate is added to culturedcells for 30 minutes where it diffuses into melanocytes and ishydrolyzed by intracellular esters to 2′,7-dichlorofluorescein (DCF)which reacts with ROS to generate fluorescent DCF. After 5 days oftreatment with 200 μM or 400 μM of 4-TBP, the generation of ROS inmelanocytes demonstrated a dose response (i.e., moderate to robust,respectively), whereas the untreated the DMSO treated melanocytesexhibited no ROS generation. When the treatment protocol included thetest compounds, UP256 (bakuchiol) demonstrated strong antioxidantproperty as shown in FIG. 3.

Example 7 Tyrosinase Inhibition Activity of a Bakuchiol Composition

Two natural bakuchiol compositions comprising 77.02% bakuchiol (100%purity) were tested for tyrosinase inhibition activity. Both materialscontained a combined total of less than 100 ppm total psoralen andangelicin (isopsoralen).

A tyrosinase inhibition assay was carried out using the method reportedby Jones et al. (2002) Pigment. Cell Res. 11:335. Using this method, theconversion of L-Dopa, a substrate of tyrosinase, into dopachrome wasfollowed by monitoring absorption at 450 nm. Tyrosinase was prepared in50 mM potassium phosphate buffer, pH 6.8 (assay buffer) at 2000 U/ml andstored at −20° C. in 1 ml aliquots prior to use. For use in assays,stock enzyme solutions were thawed and diluted to 200 U/ml with assaybuffer. A 2 mM working solution of substrate, L-DOPA, was prepared inassay buffer for each assay. Samples were dissolved in 10% DMSO (0.5 ml)and diluted to 5 ml with assay buffer. The reaction mixture comprised0.050 ml 2 mM L-DOPA, 0.050 ml 200 U/ml mushroom tyrosinase and 0.050 mlinhibitor. Reaction volume was adjusted to 200 μl with assay buffer.Assays were performed in 96 well Falcon 3097 flat-bottom microtiterplates (Beckton Dickinson, NJ). Appearance of dopachrome was measuredwith a WALLAC 1420 Multilable Counter (Turku, Finland). Average velocitywas determined from linear enzyme rate as measured by change inabsorbance (ΔA₄₅₀) at 450 nm per minute. Percent inhibition oftyrosinase by test samples was determined by comparison of absorbance ofsamples versus control using formula (1):

(Negative control absorption−sample absorption)/Negative controlabsorption×100  (1)

As shown in FIG. 4, both bakuchiol compositions showed no tyrosinaseinhibition activity, while the positive control (kojic acid) showed doseresponsive tyrosinase inhibition with and IC50 value of 63.9 μM.

Example 8 Formulation of a Bakuchiol Composition in Cosmetic Cream, Gel,and Lotion

Two natural bakuchiol compositions comprising 86.54% bakuchiol and77.02% bakuchiol were formulated in a cosmetic vehicle or complicatedskin care cream, gel or lotions as demonstrated below.

Formulation A Bakuchiol 1.0% Vitamin E acetate 0.1% Phenonip 0.5%ranseutol 98.4%

Formulation B Bakuchiol 1.0% Vitamin E acetate 0.1% Captylictriglyceride 98.4% Phenonip 0.5%

Formulation C Bakuchiol 1.0% Polysorbate-20 15.0% Transeutol 5.0%Vitamin E acetate 0.1% Purified water 78.2% Phenon ip 0.5%

TABLE 5 Formulation D No. Material INCI Name 1 D.I. WATER Water 2Gemseal 40 C15-19 AIkane 3 GLYCERIN Glycerin 4 1.3-B.G Butylene Glycol5. Carbopol #940 Carbomer 6 ARLATON 2121 Sorbitan Stearate/SucroseCocoate 7 Salacos 816T C15-19 Alkane 8 Sunflower Oil HelianthusAnnuns(Sunflower) Seed Oil 9 TREHALOSE Trehalose 10 ERITHRITOLErythritol 11 Dow Coming #345 Cyclornethicone 12 CALCOL 68 ( CETANOL)Cetanol 13 STEARIC ACID Stearic Acid (EMERSOL#132) 14 CITHROL GMSGlyceryl Stearate/PEG-100 Steam e A/S(AR #165) 15 GMS #205 GlycerylStearate SE 16 BEES WAX Beeswax 17 SODIUM Sodium Hyaluronate HYALURONATE(Hyasol) 18 Bakuchiol at 0.5% Hydrolyzed Psoralea corylifolia extract

Example 9 Evaluation of the Safety Profile of a Bakuchiol Composition

Two natural bakuchiol compositions comprising 86.54% bakuchiol and77.02% bakuchiol and a combined total of less than 100 ppm psoralen andangelicin (isopsoralen) were formulated in a cosmetic vehicle orcomplicated skin care cream and tested on in vitro models or in humanclinical trials for their safety profile. As demonstrated in Table 6,the bakuchiol compositions showed no eye irritation, no skin irritation,no skin allergic contact sensitization and no phototoxicity. Thecompositions had a solid safety profile at a broad range ofconcentration levels (20% to 100% by weight of bakuchiol) with good skinpenetration properties.

TABLE 6 Results of Bakutrol ™ Safety Testing TEST BRIEF DESCRIPTION OFTHE TEST NAME PROCEDURE RESULT EPIOCULAR This is a biological assay toevaluate ocular Test Product at the MTT toxicity or irritating potentialof a test article by l% concentration VIABILITY determining the ET50 forMTT viability of was classified in the ASSAY EpiOcular samples. minimalto non- irritating category. CHAMBER This is a clinical test to assessthe irritating The effects of 0.5% SCARIFICATION potential of chemicalcompounds. The test is of the test product performed on human subjectswhose skin was on scarified skin sensitized by scratching. The variablebeing were comparable to tested is the compound's ability to cause thesaline control at irritation of compromised skin. 72 hours. REPEATEDThis is a clinical test to assess both irritating and Under study INSULTPATCH allergenic potentials of chemical compounds. conditions the testThe test is performed by repetitive application product did not of thecompounds to the skin of healthy indicate a potential volunteers. Thevariables being tested are the for dermal irritation compound's abilityto cause erythema or edema. or allergic contact sensitization. PHOTO-This is a clinical test to assess phototoxic The test product wasTOXICITY potential of test compounds. The test is considered non-performed on human subjects by application of phototoxic the compoundsto the skin, followed by UV- according to irradiation, and up to 1 weekpost-irradiation reference at the period. The variables being tested arethe 0.5% concentration compound's ability to cause adverse or tested.unexplained reactions. AMES This is a biological assay to assess theTest product was mutagenic potential of chemical compounds. notassociated with The test uses strains of the bacterium that carry anymutagenic specific mutations. The variable being tested is changes atdoses up the mutagen's ability to cause a reversion of to 3 mg/platethese mutations. PERCUTANEOUS This is an ex-vivo test to assess skinpenetration At 0.5% formulation ABSORBTION of chemical compounds. Thetest is performed concentration, the by single application to cadaverskin. The data indicates a variable being tested is the percentage oftest good penetration compound that is absorbed into skin over a profileand certain per of time. absorption into skin over 48 hours.

Example 10 Clinical Evaluation of a Furanocoumarin-Free BakuchiolComposition

A natural bakuchiol composition (Bakutrol™) extracted and enriched fromthe seeds of Psoralea corylifolia and comprising 77.02% bakuchiol andless than 100 ppm furanocoumarin was formulated in a cosmetic skin carecream (formulation D, Example 8) and tested in a human clinical trial.The study was a pilot, open label human study to evaluate the clinicalbenefits of Bakutrol™ at 0.5% concentration after topical application.The study included 5 subjects meeting the exclusion/inclusion criteriafor evaluation of the benefits of the natural bakuchiol composition forimprovement of Post-Inflammatory Hyperpigmentation (PIH). The durationof the study was 12 weeks. The subjects were instructed to apply theBakutrol™ 0.5% cream twice a day, morning and night, and return to thesite for a total of 9 visits, including the screening visit. Theevaluation included Investigator Global Assessment of skin conditions(IGA), and Evaluation of overall grade and severity of skinPost-Inflammatory Hyperpigmentation (PIH) and other associated skinconditions, including Erythema, Dryness, Peeling, Oiliness, Safety, andTolerability. The subject questionnaires included safety and compliancequestions in relation to irritation, skin comfort, use of other productsand sunscreens. Photographs were taken at baseline, Week 4, Week 8 andWeek 12. Change from baseline in PIH severity, change from baseline inthe PIH Grade, and the proportion of success according to the IGA scalewere recorded and analyzed. The following 6 levels of PIH grade ofseverity (0=absent, 1=slight, 2=mild, 3=moderate, 4=moderately severe,5=severe) and total area of PIH affected facial surface were utilizedfor the clinical output analyses.

As shown in FIG. 5, all five subjects treated with a topical creamcomprising Bakutrol™ at 0.5% had at least one grade reduction of PIHseverity. The percentage improvement of PIH affected facial area wasmore than 50% after 8 weeks of continued application (see FIG. 6). Themean percentage and absolute grade level improvements of both PIH andits severity are summarized in FIGS. 7 & 8. Improvements of more than40%, or more than one grade level reduction of both PIH and severity,were achieved as early as 4 weeks after using a natural bakuchiolcomposition extracted and enriched from the seeds of Psoraleacorylifolia and comprising 77.02% bakuchiol and less than 100 ppmfuranocoumarin. Substantial reduction of PIH on the affected facial skinsites is clearly evident in the photos of two subjects as shown in FIG.9. Both subjects showed progressive improvement of skinPost-Inflammatory Hyperpigmentation (PIH) associated with mild andmoderate acnes after topical application of a Bakutrol™ cream.

Table 7 summarizes the clinical outputs for using a furanocoumarin-freeBakuchiol composition compared to popular acne treatment products thatcontain either an anti-microbial or an anti-inflammatory or acombination thereof. The data clearly demonstrate that thefuranocoumarin-free Bakuchiol composition not only improved inflammatoryand non-inflammatory lesion counts but also significantly improved skinPost-Inflammatory Hyperpigmentation. The PIH benefit from the Bakuchiolcomposition is unexpected based on its lack of tyrosinase inhibition asdemonstrated in Example 7.

TABLE 7 Clinical Report Summary of Bakutrol and OTC Drugs Study 3 Study4 Study 1 Study 2 12 week 12 week 10 week study * 12 week study *Study * Study * Benzaclin (5% Benzoyl Clindamycin Vehicle ClindaGelBakutrol Benzoyl Peroxide peroxide (1%) N = 120 (1% (UP256) & 1% (5%) N= 120 Clindamycin) 0.5% Clindamycin) N = 120 N = 162 N =13 N = 120 Meanpercent reduction in inflammatory lesion counts 46% 32% 16% +3% 51% 33%Mean percent reduction in non-inflammatory lesion counts 22% 22% 9% +1%25% 16% Mean percent reduction in total lesion counts 36% 28% 15% 0.2%38% 26% Improvement of Post Inflammatory Hyperpigmentation 0 0 0 0 0 62%

Example 11 Evaluation of a Furanocoumarin-Free Bakuchiol Composition onDiminishing the Effects of Post-Inflammatory Hyperpigmentation

The safety and efficacy of a 0.5% (wt/wt) cream of bakuchiol (UP256) wasevaluated in a double blind placebo and positive controlled study forthe treatment of PIH related to acne. The study evaluated a bakuchiolcream at 0.5% concentration, a 2% Salicylic acid cream and a placebocream (Vehicle) in an Asian population. The participants were instructedto apply the study creams to the face twice a day (AM/PM). Studyparticipants were given instructions for application and provided withsunscreen.

The study population consisted of male and female subjects older than 18and younger than 40 years and in generally good health as determined bya medical history. The bakuchiol study arm enrolled 18 subjects, theSalicylic acid (SAL) study arm enrolled 20 subjects, and the placebostudy arm enrolled 19 subjects.

The Investigators and study staff discussed and agreed upon a cleardefinition of PIH as related to acne or other tissue injury (which didnot include freckles (Ephilides), solar lentigo (lentigines), ormelisma). The PIH grade is a measure of the severity of thehyperpigmentation (higher number=more severe pigmentation). The patientpopulation had a PIH grade >3 and acne was mild to moderate Grade 2-3,the key factor was the PIH as related to current or past inflammatoryacne.

Primary Study Objectives:

1. PIH IGA Time Frame: Baseline and weeks 2, 4 and 8

2. PIH % Distribution Time Frame: Baseline and weeks 2, 4 and 8 PIHefficacy was evaluated based on changes from baseline (p<0.05) and overother treatment groups (p<0.05) using t-test or/and ANOVA.

Secondary Objectives: Safety Assessments

Subject's Assessment questionnaires and Tolerability Assessments werecollected at Baseline and weeks 2, 4, and 8. Urine pregnancy tests forfemales of childbearing potential were collected at Baseline and week 8.

Data Analysis

The following data was collected:

1. Change from baseline in P1H Severity;

2. Change from baseline in the PIH Grade; and

3. Change from baseline in the Lesion counts

Results:

The data was analyzed from Investigator evaluations at each visit andfrom photographs taken at the specified time points. The photographsfrom baseline, week 4, and week 8 were evaluated by a second group ofinvestigators and two independent dermatologists before the study wasunblended to further confirm that the population met criteria. The dataanalyzed is based on confirmed evaluations, there was no photo for weektwo therefore week two data is not included in the analysis. Table 8summarizes the data.

TABLE 8 PIH Grade Changes for Study Groups Bakutrol ANOVA (UP256)Baseline Week 4 Week 8 (p value) Mean 3.44 2.83 2.5 0.0083 SD 0.78 0.860,99 SEM 0.18 0.2 0.23 N 18 18 18 (t -test) 0.0005 0.0003 p value WeekWeek PLACEBO Baseline 4 8 0.9712 Mean 3 3.05 3 SD 0.82 0.71 0.67 SEM0.19 0.16 0.15 N 19 19 19 p value 0.5778 1 Week Week 2% SAL Baseline 4 80.9798 Mean 3.15 3.2 3.2 SD 0.93 0.89 0.89 SEM 0.21 0.2 0.2 N 20 20 20 pvalue 0.3299 0.3299

The Bakutrol (UP256) group showed significant change in PIH grade (i.e.,lower PIH grade) from baseline at week 8 (p<0.05). Additionally, theBakutrol group showed significant change over placebo at week 8(p<0.05). The data also show that the bakutrol treated group is the onlygroup that has a time and treatment significant p value (p=0.0083).

Table 9 Inflammatory Acne Lesions for All Groups Bakutrol Week WeekANOVA OVER (UP256) Baseline 4 8 TREATMENT TIME Mean 13.11 9 5.67 0.016SD 9 6.93 4.67 SEM 2.12 1.63 1.1 N 18 18 18 p value 0.0014 0.0001Salicylic Week Week Acid Baseline 4 8 0.513 Mean 11.2 9.25 8.65 SD 6.838.33 6.47 SEM 1.53 1.86 1.45 N 20 20 20 p value 0.0242 0.0159 Week WeekPLACEBO Baseline 4 8 0.0985 Mean 8.42 7 5.68 SD 4.38 3.83 3.22 SEM 10.88 0.74 N 19 19 19 p value 0.1367 0.0021

The Bakutrol (UP256) group showed significant change from baseline atweeks 4 and 8 (p<0.001). The Bakutrol group also showed significantchange over placebo at week 8 (p<0.05). In addition UP256 is the onlygroup that reached a greater than 50% decrease of inflammatory lesionsat 8 weeks (57%).

There were no significant changes for the Bakutrol (UP256) group in thenon-inflammatory lesion category (data not shown); however, thesalicylic acid treated groups in the non-inflammatory lesion categoryreached a p value <0.05 at 4 weeks of treatment.

TABLE 10 Summary of Questionnaire and Investigator Safety Evaluation0.5% Bakatrol 2.0% Salicylic Subject Assessment UP256 PLACEBO acidCategory 1 2 4 Itching/Burning 0 0 2 Skin Discomfort

Conclusion:

The results show that the Bakutrol (UP256) cream significantly reducedPost Inflammatory Hyperpigmentation (PIH) related to acne after only 4weeks of topical application. UP256 also significantly reducedinflammatory acne lesions (<0.05) by 57% after 8 weeks.

Bakutrol (UP256) cream had a good safety profile and was well toleratedby study participants. The cosmetic acceptability of the cream was ratedas better than, or as good as, that of their previous topicalover-the-counter (OTC) acne therapy.

Example 12 Treatment of Inflammatory and Non-Inflammatory Acne Lesions

A composition comprising both bakuchiol and salicylic acid is prepared.Patients having both inflammatory, non-inflammatory, or both types ofacne of lesions are treated with the composition. The composition iseffective to treat both inflammatory and non-inflammatory lesions with ap value <0.05 at 4 weeks of treatment. The reduction in lesions rangesfrom about 10% to about 90%.

The various embodiments described above can be combined to providefurther embodiments. All of the U.S. patents, U.S. patent applicationpublications, U.S. patent applications, foreign patents, foreign patentapplications and non-patent publications referred to in thisspecification and/or listed in the Application Data Sheet, areincorporated herein by reference, in their entirety. Aspects of theembodiments can be modified, if necessary to employ concepts of thevarious patents, applications and publications to provide yet furtherembodiments. These and other changes can be made to the embodiments inlight of the above-detailed description. In general, in the followingclaims, the terms used should not be construed to limit the claims tothe specific embodiments disclosed in the specification and the claims,but should be construed to include all possible embodiments along withthe full scope of equivalents to which such claims are entitled.Accordingly, the claims are not limited by the disclosure.

1-71. (canceled)
 72. A composition comprising bakuchiol, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier and less than 500 ppm total furanocoumarinimpurities.
 73. The composition of claim 72, wherein the compositioncomprises less than 100 ppm total furanocoumarin impurities.
 74. Thecomposition of claim 72, wherein the composition shows no tyrosinaseinhibition activity relative to a kojic acid control.
 75. Thecomposition of claim 72, wherein the furanocoumarin impurities comprisepsoralen, isopsoralen or combinations thereof.
 76. The composition ofclaim 72, wherein the composition comprises 0.001% to 99.9% by totalweight of bakuchiol and a pharmaceutically, dermatologically orcosmetically acceptable carrier.
 77. The composition of claim 72,wherein the composition is administered topically, by aerosol, bysuppository, intradermically, intramuscularly or intravenously.
 78. Thecomposition of claim 72, wherein the composition is formulated fortopical administration.
 79. The composition of claim 72, wherein thecomposition comprises from about 0.1% to about 2.0% by total weight ofbakuchiol.
 80. The composition of claim 72, wherein the compositioncomprises about 0.5% by total weight of bakuchiol.
 81. The compositionof claim 72, wherein the composition further comprises salicylic acid ora pharmaceutically acceptable salt thereof.
 82. A composition comprisingsynthetic bakuchiol, or a pharmaceutically acceptable salt thereof, anda pharmaceutically acceptable carrier and less than 500 ppm totalfuranocoumarin impurities.
 83. The composition of claim 82, wherein thecomposition comprises less than 100 ppm total furanocoumarin impurities.84. The composition of claim 82, wherein the composition shows notyrosinase inhibition activity relative to a kojic acid control.
 85. Thecomposition of claim 82, wherein the furanocoumarin impurities comprisepsoralen, isopsoralen or combinations thereof.
 86. The composition ofclaim 82, wherein the composition comprises 0.001% to 99.9% by totalweight of bakuchiol and a pharmaceutically, dermatologically orcosmetically acceptable carrier.
 87. The composition of claim 82,wherein the composition is administered topically, by aerosol, bysuppository, intradermically, intramuscularly or intravenously.
 88. Thecomposition of claim 82, wherein the composition is formulated fortopical administration.
 89. The composition of claim 82, wherein thecomposition comprises from about 0.1% to about 2.0% by total weight ofbakuchiol.
 90. The composition of claim 82, wherein the compositioncomprises about 0.5% by total weight of bakuchiol.
 91. The compositionof claim 82, wherein the composition further comprises salicylic acid ora pharmaceutically acceptable salt thereof.